Loading...

MTNB MATINAS BIOPHARMA HOLDINGS INC US FDA Inspections 8-K Filing

MTNS

MTNB

MATINAS BIOPHARMA HOLDINGS INC

(MTNB)

2023 8-K

Show Summary

Show Summary

Compensatory Arrangements o...

Stockholder Votes

Management Change

Board Resignation

Director Appointment

Director Resignation

NYSE Compliance Issue

Director Resignation

Workforce Reduction

Management Change

Stock Split Announcement

Stock Trading Halt

Share Reduction & Split

Financial Results

Financial Results Announcement

Securities Purchase Agreement

Corporate Presentation Update

Financial Results Announcement

Positive Study Results for ...

Clinical Response in Patien...

Compliance Regained with NY...

Update on Compassionate/Exp...

FDA Agreement for Phase 3 T...

Corporate Presentation Update

Product Launches

FDA Feedback on Phase 3 Stu...

Corporate Presentation Update

Positive Study Results for ...

Financial Results Announcement

Annual Meeting of Stockholders

Delisting Notice

Presentation Update

Financial Results Announcement

Financial Results and Strat...

Clinical Impact Announcement

Financial Results Announcement

Business Update and Strateg...

Collaboration Announcement

External Links:

Matinas BioPharma Holdings, Inc. announced receipt of written feedback from the FDA on its proposed revised protocol for a Phase 3 study of MAT2203 in patients with invasive aspergillosis.

AI Assistant

MATINAS BIOPHARMA HOLDINGS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.